Iovance Biotherapeutics
IOVA
IOVA
285 hedge funds and large institutions have $2.21B invested in Iovance Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 108 increasing their positions, 84 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
3% less funds holding
Funds holding: 295 → 285 (-10)
5.6% less ownership
Funds ownership: 83.1% → 77.51% (-5.6%)
17% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 46
Holders
285
Holding in Top 10
9
Calls
$44.1M
Puts
$24.7M
Top Buyers
| 1 | +$51.3M | |
| 2 | +$36.1M | |
| 3 | +$30.2M | |
| 4 |
Goldman Sachs
New York
|
+$16.8M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$14.2M |
Top Sellers
| 1 | -$70.7M | |
| 2 | -$22.6M | |
| 3 | -$14.6M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$12.9M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$12.5M |